Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Shattuck Labs, Inc. (STTK : NSDQ)

• Company Description    Shattuck Labs Inc. is a clinical-stage biotechnology company. It engages in development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. The company's wholly owned program includes SL-172154. It operates principally in Durham, North Carolina and Austin, Texas. Shattuck Labs Inc. is based in Austin, United States. Number of Employees: 105

• Price / Volume Information    Yesterday's Closing Price: $2.87 Daily Weekly Monthly 20 Day Moving Average: 32,672 shares Shares Outstanding: 42.47 (millions) Market Capitalization: $121.89 (millions) Beta: 1.09 52 Week High: $5.82 52 Week Low: $1.85 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 2.50% -1.38% 12 Week -0.35% -7.49% Year To Date 24.78% 13.50%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 500 W. 5TH STREET SUITE 1200 - AUSTIN,TX 78701 USA ph: 512-900-4690 fax: - investorrelations@shattucklabs.com http://www.shattucklabs.com

• General Corporate Information    Officers Taylor Schreiber - Chief Executive Officer and Director George Golumbeski - Chairman Andrew R. Neill - Chief Financial Officer Helen M. Boudreau - Director Neil Gibson - Director Peer Information Shattuck Labs, Inc. (CORR.) Shattuck Labs, Inc. (RSPI) Shattuck Labs, Inc. (CGXP) Shattuck Labs, Inc. (BGEN) Shattuck Labs, Inc. (GTBP) Shattuck Labs, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 82024L103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/23 Next Expected EPS Date: 08/10/23 Share - Related Items Shares Outstanding: 42.47 Most Recent Split Date: (:1) Beta: 1.09 Market Capitalization: $121.89 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.52 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.98 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/10/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.77 Price/Cash Flow: - Price / Sales: 169.53 EPS Growth vs. Year Ago Period: 15.52% vs. Previous Quarter: 18.33% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -85.38% ROE 03/31/23 - -51.94 12/31/22 - -48.14 09/30/22 - -29.15 ROA 03/31/23 - -45.79 12/31/22 - -42.92 09/30/22 - -26.33 Current Ratio 03/31/23 - 9.86 12/31/22 - 7.39 09/30/22 - 10.53 Quick Ratio 03/31/23 - 9.86 12/31/22 - 7.39 09/30/22 - 10.53 Operating Margin 03/31/23 - -13,649.65 12/31/22 - - 09/30/22 - - Net Margin 03/31/23 - -13,649.65 12/31/22 - - 09/30/22 - - Pre-Tax Margin 03/31/23 - -13,649.65 12/31/22 - -15,635.74 09/30/22 - -226.32 Book Value 03/31/23 - 3.71 12/31/22 - 4.16 09/30/22 - 4.71 Inventory Turnover 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Equity 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00 Debt-to-Capital 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00

Powered by Zacks Investment Research ©